Good News For This Small-Cap Biotech: Eli Lilly Wants To Develop Its Diabetes Drug [View article]
Yes, a ways out. At this point, LLY has the drug for a $7M GAIN (net of milestone and payment from TTHI) and can always buy TTHI at a later point to avoid shelling out milestones and royalties. No matter how good the data look, there's still clinical risk going through two more stages of trials - large trials at that.
Would you pay $100M+ now, or book $7M with the option to buy later?
Good News For This Small-Cap Biotech: Eli Lilly Wants To Develop Its Diabetes Drug [View article]
Yes, a ways out. At this point, LLY has the drug for a $7M GAIN (net of milestone and payment from TTHI) and can always buy TTHI at a later point to avoid shelling out milestones and royalties. No matter how good the data look, there's still clinical risk going through two more stages of trials - large trials at that.
Which would you pay $100M+ now or book $7M with the option to buy later?
Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide [View article]
Not suggesting holding exclusively for sale, although exposure is part of the thesis, but we suspect there's more upside in interim than most give credit for. Just won't be retail driven. Company will probably hit the road to meet with investors now that they've got strong POC, balance sheet, easy comps. Again, anyone who'll listen. Not to mention IBs talking their book; they still need to support the last deal.
Yes, don't miss the rest of the bull market though. =)
Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide [View article]
Agree to an extent Shane, but you've got to acknowledge that sophisticated investors already assume quality IBS-C results given GC-C history. The market will make it into more of a catalyst than it is, but the more interesting story in our view is how the company executes in the interim. Management has certainly made it no secret that a sale is top priority, and the company will be out pounding the table with anyone who'll listen in the interim.
MAKO Surgical: Burden Of Proof Still On Management [View article]
"Time will tell if Mako has regained it's footing. If they have, many will be kicking themselves over the missed opportunity to buy MAKO near all time lows."
Agreed, but for a $500M company, there's a lot of downside to this story if things don't pan out as management has guided. This is an enticing turnaround play, but the bottom line is that Q1 wasn't convincing enough for us to be buyers.
Questcor: Firing On All Cylinders, Earnings Next Tuesday, Shorts Covering [View article]
Our model for fair value is linked in the above article; it can be found in an earlier report. We've actually said just the same thing, that QCOR is worth between $37 and $46.
Good News For This Small-Cap Biotech: Eli Lilly Wants To Develop Its Diabetes Drug [View article]
Would you pay $100M+ now, or book $7M with the option to buy later?
Good News For This Small-Cap Biotech: Eli Lilly Wants To Develop Its Diabetes Drug [View article]
Which would you pay $100M+ now or book $7M with the option to buy later?
Synergy On Sale: Why This Opportunity Shouldn't Be Missed [View article]
Markman Hearing A Likely Clearing Event For Cubist - Decision Any Day [View article]
Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide [View article]
Yes, don't miss the rest of the bull market though. =)
Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide [View article]
Value Investors Take Note: Fire Sale On This Heart Failure Asset [View article]
MAKO Surgical: Burden Of Proof Still On Management [View article]
Agreed, but for a $500M company, there's a lot of downside to this story if things don't pan out as management has guided. This is an enticing turnaround play, but the bottom line is that Q1 wasn't convincing enough for us to be buyers.
Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval [View article]
Zogenix Poised For 40% Haircut As Zohydro Decision Approaches [View article]
Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval [View article]
What You Need To Know About Keryx And Zerenex's IP [View article]
Allergic Reactions To Affymax's Single Product Are Crushing [View article]
Questcor: Firing On All Cylinders, Earnings Next Tuesday, Shorts Covering [View article]
Questcor: Firing On All Cylinders, Earnings Next Tuesday, Shorts Covering [View article]